Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

5.190 +0.140 (+2.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,162,464
Open 5.070
Bid (Size) 5.130 (4,300)
Ask (Size) 5.220 (300)
Prev. Close 5.050
Today's Range 5.010 - 5.250
52wk Range 2.900 - 10.08
Shares Outstanding 25,938,064
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Immuneering Appoints Andrew Gengos as Chief Financial Officer
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire

Performance

YTD
-21.6%
-21.6%
1 Month
+21.3%
+21.3%
3 Month
-4.8%
-4.8%
6 Month
-21.6%
-21.6%
1 Year
+44.6%
+44.6%

More News

Read More
News headline image
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
From Immuneering Corporation
Via GlobeNewswire
Friday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
From Immuneering Corporation
Via GlobeNewswire
IMRX Stock Closed Over 20% Higher Today: Here’s Why ↗
Via Stocktwits
News headline image
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Leerink Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Immuneering Corporation
Via GlobeNewswire
Here are the top movers in Thursday's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
Via FinancialNewsMedia
News headline image
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
From FN Media Group LLC
Via GlobeNewswire

Frequently Asked Questions

Is Immuneering Corporation - Class A Common Stock publicly traded?
Yes, Immuneering Corporation - Class A Common Stock is publicly traded.
What exchange does Immuneering Corporation - Class A Common Stock trade on?
Immuneering Corporation - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immuneering Corporation - Class A Common Stock?
The ticker symbol for Immuneering Corporation - Class A Common Stock is IMRX on the Nasdaq Stock Market
What is the current price of Immuneering Corporation - Class A Common Stock?
The current price of Immuneering Corporation - Class A Common Stock is 5.190
When was Immuneering Corporation - Class A Common Stock last traded?
The last trade of Immuneering Corporation - Class A Common Stock was at 07/02/26 04:00 PM ET
What is the market capitalization of Immuneering Corporation - Class A Common Stock?
The market capitalization of Immuneering Corporation - Class A Common Stock is 134.62M
How many shares of Immuneering Corporation - Class A Common Stock are outstanding?
Immuneering Corporation - Class A Common Stock has 135M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS